XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.86

+0.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (7859)	11/27/1998 7:05:00 PM
From: aknahow	Read Replies (1) of 17367

Bluegreen, I don't think we are talking about revenue generated in the U.S. from product sales. "If we succeed with NEUPREX®, we anticipate a significant portion of our future revenue will originate outside the United States," IF WE SUCCEED.. WE ANTICIPATE...A...PORTION OF...REVENUE WILL ORIGINATE OUTSIDE THE U.S. I think U.S. revenue, not necessarily royalty income from others located in the U.S. will end up paying some sort of U.S. tax. But I await the prospectus for clarification. BTW posting and reading post should have disabused you of thinking there are any reasonable people, so your second question is just plain stupid.<g> Seriously, when one says, IF SUCCESSFUL we expect to sell what we were successful at developing does not sound like much hype to me. To add that some of those sales would be made outside of the U.S. sounds logical and not like hype. The final word came from the market. The statements were not taken as hype. The stock did not rise to $20 in anticipation of success and huge foreign market for Neuprex and other drugs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next